WO2002026774A3 - Melanocortin receptor ligands - Google Patents

Melanocortin receptor ligands Download PDF

Info

Publication number
WO2002026774A3
WO2002026774A3 PCT/US2001/030051 US0130051W WO0226774A3 WO 2002026774 A3 WO2002026774 A3 WO 2002026774A3 US 0130051 W US0130051 W US 0130051W WO 0226774 A3 WO0226774 A3 WO 0226774A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
receptor ligands
melanocortin receptor
formula
disclosed
Prior art date
Application number
PCT/US2001/030051
Other languages
French (fr)
Other versions
WO2002026774A2 (en
Inventor
Frank Hallock Ebetino
Adam W Mazur
Jeffrey Charles Hayes
Feng Wang
Mark Gregory Solinsky
Anny-Odile Colson
Qishen Lin
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002531157A priority Critical patent/JP2004509974A/en
Priority to EP01977175A priority patent/EP1409540A2/en
Priority to NZ524190A priority patent/NZ524190A/en
Priority to PL36200301A priority patent/PL362003A1/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to HU0303085A priority patent/HUP0303085A2/en
Priority to AU9631301A priority patent/AU9631301A/en
Priority to KR10-2003-7004415A priority patent/KR100519204B1/en
Priority to MXPA03002691A priority patent/MXPA03002691A/en
Priority to AU2001296313A priority patent/AU2001296313B2/en
Priority to IL15443701A priority patent/IL154437A0/en
Priority to BR0114257-7A priority patent/BR0114257A/en
Priority to CA002420045A priority patent/CA2420045A1/en
Publication of WO2002026774A2 publication Critical patent/WO2002026774A2/en
Priority to NO20031287A priority patent/NO20031287D0/en
Publication of WO2002026774A3 publication Critical patent/WO2002026774A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)

Abstract

Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R?2, R4, R4', R5, R6, R6', R7, R8, R8', R9, R9', R10, Ar, Z1, Z2, Z3¿, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.
PCT/US2001/030051 2000-09-27 2001-09-26 Melanocortin receptor ligands WO2002026774A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU9631301A AU9631301A (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
NZ524190A NZ524190A (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
PL36200301A PL362003A1 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
MXPA03002691A MXPA03002691A (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands.
HU0303085A HUP0303085A2 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands and pharmaceutical compositions containing them
EP01977175A EP1409540A2 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
KR10-2003-7004415A KR100519204B1 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
JP2002531157A JP2004509974A (en) 2000-09-27 2001-09-26 Melanocortin receptor ligand
AU2001296313A AU2001296313B2 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
IL15443701A IL154437A0 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
BR0114257-7A BR0114257A (en) 2000-09-27 2001-09-26 Melanocortin Receptor Ligands
CA002420045A CA2420045A1 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands
NO20031287A NO20031287D0 (en) 2000-09-27 2003-03-20 Melanokortinreseptorligander

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23585800P 2000-09-27 2000-09-27
US60/235,858 2000-09-27

Publications (2)

Publication Number Publication Date
WO2002026774A2 WO2002026774A2 (en) 2002-04-04
WO2002026774A3 true WO2002026774A3 (en) 2003-03-27

Family

ID=22887187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030051 WO2002026774A2 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands

Country Status (19)

Country Link
EP (1) EP1409540A2 (en)
JP (1) JP2004509974A (en)
KR (1) KR100519204B1 (en)
CN (1) CN1571796A (en)
AR (1) AR030806A1 (en)
AU (2) AU9631301A (en)
BR (1) BR0114257A (en)
CA (1) CA2420045A1 (en)
CZ (1) CZ2003788A3 (en)
HU (1) HUP0303085A2 (en)
IL (1) IL154437A0 (en)
MX (1) MXPA03002691A (en)
NO (1) NO20031287D0 (en)
NZ (1) NZ524190A (en)
PE (1) PE20020447A1 (en)
PL (1) PL362003A1 (en)
RU (1) RU2246501C2 (en)
WO (1) WO2002026774A2 (en)
ZA (1) ZA200301561B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174950B2 (en) 2009-07-06 2015-11-03 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US9284285B2 (en) 2006-06-27 2016-03-15 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
ATE550041T1 (en) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
RU2309144C2 (en) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Phenyl-containing n-acylamine derivatives, method for production thereof, pharmaceutical composition and uses thereof as anti-inflammatory and analgesic agents
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
MX2008012991A (en) 2006-04-07 2008-10-17 Procter & Gamble Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof.
RU2303597C1 (en) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Pharmaceutical composition, method for its preparing and using
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
MX2010013436A (en) 2008-06-09 2011-06-21 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of sexual dysfunction.
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
MX2011013117A (en) 2009-06-08 2012-05-23 Palatin Technologies Inc Melanocortin receptor-specific peptides.
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
RU2012125033A (en) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. SYNTHESIS METHOD Ac-Arg-CYCLO (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH2
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc Melanocortin-1 receptor-specific linear peptides
CN102725305B (en) 2009-11-23 2016-08-24 帕拉丁科技公司 Melanocortin-1 receptor-specific cyclic peptide
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
RU2016143558A (en) 2014-05-12 2018-06-13 Кэпэситор Сайенсиз Инкорпорейтед DEVICE FOR STORING ENERGY AND METHOD FOR ITS MANUFACTURE
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
AU2015343211A1 (en) 2014-11-04 2017-04-27 Capacitor Sciences Incorporated Energy storage devices and methods of production thereof
CA2977776A1 (en) 2015-02-26 2016-09-01 Capacitor Sciences Incorporated Self-healing capacitor and methods of production thereof
US9932358B2 (en) * 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
CN106966927B (en) * 2017-04-13 2018-10-09 菲立化学工程（上海）有限公司 A kind of synthetic method of anti-AIDS drug centre diazo ketone and chlorine ketone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058361A1 (en) * 1999-03-29 2000-10-05 The Procter & Gamble Company Melanocortin receptor ligands
WO2001000224A1 (en) * 1999-06-29 2001-01-04 Palatin Technologies Inc. Compositions and methods for treatment of sexual dysfunction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021571A1 (en) * 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058361A1 (en) * 1999-03-29 2000-10-05 The Procter & Gamble Company Melanocortin receptor ligands
WO2001000224A1 (en) * 1999-06-29 2001-01-04 Palatin Technologies Inc. Compositions and methods for treatment of sexual dysfunction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAN E A: "Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming brhaviour of rats", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 378, 1999, pages 249 - 258, XP002192102, ISSN: 0014-2999 *
SCHIOETH H B ET AL: "BINDING OF CYCLIC AND LINEAR MSH CORE PEPTIDES TO THE MELANOCORTIN RECEPTOR SUBTYPES", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 319, no. 2/3, 1997, pages 369 - 373, XP000906899, ISSN: 0014-2999 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284285B2 (en) 2006-06-27 2016-03-15 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US9174950B2 (en) 2009-07-06 2015-11-03 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells

Also Published As

Publication number Publication date
PL362003A1 (en) 2004-10-18
NO20031287L (en) 2003-03-20
IL154437A0 (en) 2003-09-17
AU2001296313B2 (en) 2005-06-02
AU9631301A (en) 2002-04-08
HUP0303085A2 (en) 2003-12-29
ZA200301561B (en) 2004-03-10
BR0114257A (en) 2003-07-01
RU2246501C2 (en) 2005-02-20
NZ524190A (en) 2004-09-24
NO20031287D0 (en) 2003-03-20
CA2420045A1 (en) 2002-04-04
PE20020447A1 (en) 2002-07-02
CZ2003788A3 (en) 2003-08-13
CN1571796A (en) 2005-01-26
KR100519204B1 (en) 2005-10-06
MXPA03002691A (en) 2003-06-06
KR20030061814A (en) 2003-07-22
WO2002026774A2 (en) 2002-04-04
AR030806A1 (en) 2003-09-03
JP2004509974A (en) 2004-04-02
EP1409540A2 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
WO2002026774A3 (en) Melanocortin receptor ligands
MXPA02012905A (en) Colchinol derivatives as vascular damaging agents.
BG106013A (en) New compounds and compositions as protease inhibitors
AP2002002637A0 (en) Novel piperazine
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
MY142768A (en) Gfat inhibitors
HK1081199A1 (en) Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3- azabicyclo [3,1,0] hexane-2-carboxylates or salts thereof
CA2362394A1 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
NZ308462A (en) Preparation of pure enantiomers of tropic acid esters of amino alcohols
CA2206532A1 (en) Novel amidinonaphthyl derivative or salt thereof
BG106585A (en) Kinase inhibitors as therapeutic agents
WO1998028268A3 (en) CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
CA2113229A1 (en) Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
HK1013289A1 (en) Naphthalene derivatives as prostaglandin 12 agonists
WO2004058679A3 (en) Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2001090071A3 (en) Substituted iminoazines used as herbicides
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
CA2368823A1 (en) Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
IL166513A0 (en) Lamellarin derivatives and pharmaceutical compositions containing the same
MXPA03011954A (en) Novel sulfonic acid derivatives.
MX9704856A (en) Substituted indazole derivatives.
WO2002032901A3 (en) Bridged piperazine derivatives
AU2001282871A1 (en) Antithrombotic agents
WO2000046210A3 (en) New process for preparing pesticidal intermediates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 154437

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 524190

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 180/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2420045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/01561

Country of ref document: ZA

Ref document number: 200301561

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 03021124

Country of ref document: CO

Ref document number: 03021124A

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PV2003-788

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001296313

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002691

Country of ref document: MX

Ref document number: 1020037004415

Country of ref document: KR

Ref document number: 2002531157

Country of ref document: JP

Ref document number: 01816384X

Country of ref document: CN

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

Ref document number: 2003112211

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020037004415

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-788

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001977175

Country of ref document: EP

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 2001977175

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 524190

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524190

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020037004415

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001296313

Country of ref document: AU